Literature DB >> 24067429

Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Evan D Kharasch1, Kristi Stubbert.   

Abstract

Plasma concentrations of orally administered methadone are reduced by the human immunodeficiency virus protease inhibitor combination ritonavir and lopinavir, but the mechanism is unknown. Methadone metabolism, clearance, and drug interactions have been attributed to CYP3A4, but this remains controversial. This investigation assessed the effects of acute (2 days) and steady-state (2 weeks) ritonavir-lopinavir on intravenous and oral methadone metabolism and clearance, hepatic and intestinal CYP3A4/5 activity (using the probe substrate intravenous and oral alfentanil), and intestinal transporter activity (using oral fexofenadine) in healthy volunteers. Plasma and urine concentrations of methadone and metabolite enantiomers, and other analytes, were determined by mass spectrometry. Acute and chronic ritonavir-lopinavir reduced plasma methadone enantiomer concentrations in half, with an average 2.6- and 1.5-fold induction of systemic and apparent oral methadone clearances. Induction was attributable to stereoselectively increased hepatic methadone N-demethylation, hepatic extraction, and hepatic clearance, and there was a strong correlation between methadone N-demethylation and clearance. Methadone renal clearance was unchanged. Alfentanil's systemic clearance and hepatic extraction, apparent oral clearance, and intestinal extraction were reduced to 25%, 16%, and 35% of control, indicating strong inhibition of hepatic and intestinal CYP3A activities. Ritonavir-lopinavir (acute > chronic) increased fexofenadine exposure, suggesting intestinal P-glycoprotein inhibition. No correlation was found between methadone clearance and CYP3A activity. Acute and steady-state ritonavir-lopinavir stereoselectively induced methadone N-demethylation and clearance, despite significant inhibition of hepatic and intestinal CYP3A activity. Ritonavir-lopinavir inhibited intestinal transporters activity but had no effect on methadone bioavailability. These results do not support a significant role for CYP3A or ritonavir-lopinavir-inhibitable intestinal transporters in single-dose methadone disposition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067429      PMCID: PMC3834136          DOI: 10.1124/dmd.113.053991

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  60 in total

1.  Time-dependent interaction between lopinavir/ritonavir and fexofenadine.

Authors:  Rolf P G van Heeswijk; Marc Bourbeau; Pearl Campbell; Isabelle Seguin; Bobby M Chauhan; Brian C Foster; D William Cameron
Journal:  J Clin Pharmacol       Date:  2006-07       Impact factor: 3.126

2.  Surveillance of methadone-related adverse drug events using multiple public health data sources.

Authors:  Shannon A Sims; Laverne A Snow; Christina A Porucznik
Journal:  J Biomed Inform       Date:  2006-11-01       Impact factor: 6.317

Review 3.  Methadone-related deaths.

Authors:  Lynn R Webster
Journal:  J Opioid Manag       Date:  2005 Sep-Oct

4.  Enantiomeric metabolic interactions and stereoselective human methadone metabolism.

Authors:  Rheem A Totah; Kyle E Allen; Pamela Sheffels; Dale Whittington; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2007-01-26       Impact factor: 4.030

5.  ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.

Authors:  Séverine Crettol; Jean-Jacques Déglon; Jacques Besson; Marina Croquette-Krokar; Robert Hämmig; Isabelle Gothuey; Martine Monnat; Chin B Eap
Journal:  Clin Pharmacol Ther       Date:  2006-12       Impact factor: 6.875

6.  Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.

Authors:  D G Bailey; G K Dresser; B F Leake; R B Kim
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

Review 7.  Methadone for cancer pain.

Authors:  A B Nicholson
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

8.  Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.

Authors:  E D Kharasch; A Walker; N Isoherranen; C Hoffer; P Sheffels; K Thummel; D Whittington; D Ensign
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

9.  Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.

Authors:  B Lüthi; A Huttner; R F Speck; N J Mueller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-05       Impact factor: 5.103

10.  Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.

Authors:  Ignacio Ortega; Monica Rodriguez; Elena Suarez; Juan Jose Perez-Ruixo; Rosario Calvo
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.580

View more
  9 in total

1.  Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Authors:  Kelly E Dooley; Anne F Luetkemeyer; Jeong-Gun Park; Reena Allen; Yoninah Cramer; Stephen Murray; Deborah Sutherland; Francesca Aweeka; Susan L Koletar; Florence Marzan; Jing Bao; Rada Savic; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 2.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

3.  Differences in Methadone Metabolism by CYP2B6 Variants.

Authors:  Sarah Gadel; Christina Friedel; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2015-04-20       Impact factor: 3.922

4.  Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.

Authors:  Stéphane Mouly; Vanessa Bloch; Katell Peoc'h; Pascal Houze; Laurence Labat; Kamilia Ksouda; Guy Simoneau; Xavier Declèves; Jean Francois Bergmann; Jean-Michel Scherrmann; Jean-Louis Laplanche; Jean-Pierre Lepine; Florence Vorspan
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

5.  Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients.

Authors:  Suyun Lei; Lizhu Hong; Cuixian Yang; Shuang Zhang; Yanyun Zhang; Shizhen Huang; Ronghui Xie; Xia Li; Qing Ma; Huiqin Li
Journal:  Expert Rev Clin Pharmacol       Date:  2019-05-15       Impact factor: 5.045

6.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

7.  Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease.

Authors:  Jennifer Horst; Melissa Frei-Jones; Elena Deych; William Shannon; Evan D Kharasch
Journal:  Pediatr Blood Cancer       Date:  2016-08-30       Impact factor: 3.167

8.  Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.

Authors:  Konrad Meissner; Jane Blood; Amber M Francis; Viktar Yermolenka; Evan D Kharasch
Journal:  Anesthesiology       Date:  2014-12       Impact factor: 7.892

9.  Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.

Authors:  Takao Yamazaki; Amit Desai; Ronald Goldwater; David Han; Corrie Howieson; Shahzad Akhtar; Donna Kowalski; Christopher Lademacher; Helene Pearlman; Diane Rammelsberg; Robert Townsend
Journal:  Clin Pharmacol Drug Dev       Date:  2016-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.